Sofosbuvir/Velpatasvir/Voxilaprevir + Emtricitabine = Unknown or no reaction

Effect on Concentration

Sofosbuvir/Velpatasvir/Voxilaprevir
No change
Applies within class?
No
Emtricitabine
No change
Applies within class?
No

Pharmacologic Effects

Sofosbuvir/Velpatasvir/Voxilaprevir
Effect
N/A
Applies within class?
No
Emtricitabine
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 20-Jul-2018

Summary

Sources

Sofosbuvir/Velpatasvir/Voxilaprevir versus Emtricitabine ^

Study Design

The Phase 1 program evaluated DDIs between sofosbuvir/velpatasvir/voxilaprevir (S/V/V) and drug transporter and CYP probes, immunosuppressants, HIV antiretrovirals (ARV), and oral contraceptives (OC). S/V/V 400/100/ 100 mg ± VOX 100 mg was administered to healthy volunteers to achieve systemic VOX exposures observed across the HCV-infected patient population, as appropriate.

Study Results

S/V/V did not alter the PK of bictegravir, cobicistat, darunavir, elvitegravir, emtricitabine, rilpivirine, tenofovir alafenamide (TAF) or Tenofovir (from TAF or tenofovir disoproxil fumarate). Unboosted ARV regimens generally did not alter SOF, GS-331007, VEL or VOX PK except VEL AUC was ↓53% when administered with efavirenz (EFV); co-use of EFV with S/V/V is not recommended.

Study Conclusions

The authors concluded that sofosbuvir/velpatasvir/voxilaprevir could be safely coadministered with Emtricitabine

References

Garrison KL, Kirby B, Stamm LM, Ma G, Vu A. Drug-drug interaction profile of sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination. Ilc: International Liver Conference. Amsterdam, Netherlands. 2017; April 2017.